Patent ID: 9062115
Filing Date: 2015-06-23
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating haemophilia A comprising administering, to a patient in need thereof, a monoclonal Factor VIII antibody having the ability to bind to activated human Factor VIII, wherein said antibody, upon binding to activated Factor VIII, reduces dissociation of the A2 domain, wherein said antibody does not interfere with von Willebrand Factor (vWF) binding, wherein the light chain of said monoclonal antibody contains CDR1 of SEQ ID NO:11, CDR2 of SEQ ID NO:12, and CDR3 of SEQ ID NO:13, and a heavy chain of said monoclonal antibody contains CDR1 of SEQ ID NO:6, CDR2 of SEQ ID NO:7, and CDR3 of SEQ ID NO:8, and wherein said administration results in improved clot formation.